News

PipelineReview.com2h
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA ®, the Company’s approved respiratory ...
PipelineReview.com3h
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
BASEL, Switzerland I June 1, 2025 I Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety ...
PipelineReview.com3h
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
PARIS, France and CAMBRIDGE, MA, USA I June 2, 2025 I Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical ...
PipelineReview.com3h
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
COPENHAGEN, Denmark I June 2, 2025 I Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and ...
PipelineReview.com3h
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, China I June 1, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...
PipelineReview.com3h
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
TOKYO, Japan and Cambridge, UK I June 02, 2025 I Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a ...
PipelineReview.com19h
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting ...
PipelineReview.com1d
Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
NANJING, China I May 31, 2025 I Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a ...
PipelineReview.com1d
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast ...
PipelineReview.com2d
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK, NY, USA I May 30, 2025 I Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase ...
PipelineReview.com1d
Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, CT and NEW YORK, NY, USA I May 31, 2025 I Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase ...
PipelineReview.com2d
HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options
CHICAGO, IL, USA I May 30, 2025 I Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at ...